dr. birrer discusses the gog0218 and icon7 trials
Published 12 years ago • 471 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
4:43
understanding gog-0218 & icon7 trials
-
4:04
gog-0218 and icon7 trial regimens as maintenance therapy
-
1:50
dr. birrer on the ovarian cancer avastin os benefit
-
1:34
dr. birrer discusses recurrent ovarian cancer treatment
-
1:58
dr. birrer on the approval process in ovarian cancer
-
6:35
asco 2018: dr. birrer on practice-changing ovarian cancer studies
-
50:35
the critical role of surgery in ovarian cancer
-
8:03
bevacizumab in platinum-sensitive ovarian cancer
-
57:47
the effectiveness of bevacizumab (avastin) and related trials
-
3:16
dr. michael birrer on bevacizumab in ovarian cancers
-
1:15
dr. birrer on fda approval of rucaparib in ovarian cancer
-
1:16
dr. birrer on the need for novel treatment options in cervical cancer
-
1:49
dr. birrer on parp inhibitors in ovarian cancer
-
1:56
dr. birrer on parp inhibitors in ovarian cancer
-
1:04
michael birrer discusses personalization of ovarian cancer care
-
2:34
dr. birrer on other targets in ovarian cancer
-
0:52
dr. birrer on checkpoint inhibitors for endometrial cancer
-
0:45
dr. birrer on prevalence of cervical cancer in the united states
-
1:08
dr. burger on the use of bevacizumab in ovarian cancer
-
1:40
dr. burger on the toxicity profile of bevacizumab in ovarian cancer
-
2:30
dr. birrer on parp inhibitors in ovarian cancer
-
6:03
gog-0218: frontline bevacizumab in ovarian cancer